| Chelsey Lin Zeltinger, NP | |
|
800 4th St N, Carrington, ND 58421 | |
| (701) 652-3141 | |
| Not Available |
| Full Name | Chelsey Lin Zeltinger |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 800 4th St N, Carrington, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356865497 | NPI | - | NPPES |
| 1471919 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R39098 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carrington Health Center | Carrington, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carrington Health Center | 0547177552 | 13 |
News Archive
Vitala™ a novel, non-invasive continence control device, demonstrated safety and efficacy in providing up to 8 hours of temporary continence to people with an end colostomy, according to results of a study published in the journal Diseases of the Colon & Rectum.
Scientists at Nanyang Technological University, Singapore (NTU Singapore) have developed insulin nanoparticles that may one day become the basis for an oral medicine, and an alternative to insulin injections for diabetic patients.
ALISON, the global free learning pioneer has launched a free course entitled "Zika Virus – What you need to know". The course has been developed by ALISON Pedagogic experts within the guidance issued by the World Health Organisation and the US-based Centre for Disease Control.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early detection of cancer, today announced the launch of an MRI product suite for breast, prostate, and other organs. The product suite, which is a comprehensive quantitative image analysis solution, brings together the company's current products SpectraLook® and VividLook® with the new OmniLook™ and VersaVue™ Enterprise, to offer a comprehensive quantitative image analysis suite.
› Verified 1 days ago
| Entity Name | Carrington Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558389338 PECOS PAC ID: 0547177552 Enrollment ID: O20040810000314 |
News Archive
Vitala™ a novel, non-invasive continence control device, demonstrated safety and efficacy in providing up to 8 hours of temporary continence to people with an end colostomy, according to results of a study published in the journal Diseases of the Colon & Rectum.
Scientists at Nanyang Technological University, Singapore (NTU Singapore) have developed insulin nanoparticles that may one day become the basis for an oral medicine, and an alternative to insulin injections for diabetic patients.
ALISON, the global free learning pioneer has launched a free course entitled "Zika Virus – What you need to know". The course has been developed by ALISON Pedagogic experts within the guidance issued by the World Health Organisation and the US-based Centre for Disease Control.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early detection of cancer, today announced the launch of an MRI product suite for breast, prostate, and other organs. The product suite, which is a comprehensive quantitative image analysis solution, brings together the company's current products SpectraLook® and VividLook® with the new OmniLook™ and VersaVue™ Enterprise, to offer a comprehensive quantitative image analysis suite.
› Verified 1 days ago
| Entity Name | Mercy Hospital Of Devils Lake |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790751170 PECOS PAC ID: 9537128681 Enrollment ID: O20041005001141 |
News Archive
Vitala™ a novel, non-invasive continence control device, demonstrated safety and efficacy in providing up to 8 hours of temporary continence to people with an end colostomy, according to results of a study published in the journal Diseases of the Colon & Rectum.
Scientists at Nanyang Technological University, Singapore (NTU Singapore) have developed insulin nanoparticles that may one day become the basis for an oral medicine, and an alternative to insulin injections for diabetic patients.
ALISON, the global free learning pioneer has launched a free course entitled "Zika Virus – What you need to know". The course has been developed by ALISON Pedagogic experts within the guidance issued by the World Health Organisation and the US-based Centre for Disease Control.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early detection of cancer, today announced the launch of an MRI product suite for breast, prostate, and other organs. The product suite, which is a comprehensive quantitative image analysis solution, brings together the company's current products SpectraLook® and VividLook® with the new OmniLook™ and VersaVue™ Enterprise, to offer a comprehensive quantitative image analysis suite.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chelsey Lin Zeltinger, NP 800 4th St N, Carrington, ND 58421-1217 Ph: () - | Chelsey Lin Zeltinger, NP 800 4th St N, Carrington, ND 58421 Ph: (701) 652-3141 |
News Archive
Vitala™ a novel, non-invasive continence control device, demonstrated safety and efficacy in providing up to 8 hours of temporary continence to people with an end colostomy, according to results of a study published in the journal Diseases of the Colon & Rectum.
Scientists at Nanyang Technological University, Singapore (NTU Singapore) have developed insulin nanoparticles that may one day become the basis for an oral medicine, and an alternative to insulin injections for diabetic patients.
ALISON, the global free learning pioneer has launched a free course entitled "Zika Virus – What you need to know". The course has been developed by ALISON Pedagogic experts within the guidance issued by the World Health Organisation and the US-based Centre for Disease Control.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early detection of cancer, today announced the launch of an MRI product suite for breast, prostate, and other organs. The product suite, which is a comprehensive quantitative image analysis solution, brings together the company's current products SpectraLook® and VividLook® with the new OmniLook™ and VersaVue™ Enterprise, to offer a comprehensive quantitative image analysis suite.
› Verified 1 days ago
Richard Joseph Macker, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 800 4th St N, Carrington, ND 58421 Phone: 701-652-7137 | |
Ryan Anton Keffeler, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 800 4th St S, Carrington, ND 58421 Phone: 701-652-3141 | |
Brittany Leigh Long, APRN, PMHNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 800 4th St N, Carrington, ND 58421 Phone: 701-652-2515 | |
Mr. Brian Allen Stanley, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 800 4th St N, Carrington, ND 58421 Phone: 701-652-3141 |